These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15347038)

  • 1. [A comparative evaluation of immunomodulating drugs in the treatment of remitting multiple sclerosis].
    Zvartau ME; Kaon K; Lisak RF; Kan OA; Skoromets AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(7):66-71. PubMed ID: 15347038
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis.
    Khan O; Zabad R; Caon C; Zvartau-Hind M; Tselis A; Lisak R
    CNS Drugs; 2002; 16(8):563-78. PubMed ID: 12096936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Glatiramer acetate (Copaxone) influence on different stages of multiple sclerosis pathogenesis].
    Shmidt TE; Zhuchenko TD; Iakhno NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):79-82. PubMed ID: 12938640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results of open post-registration clinical trials of copaxone in patients with multiple sclerosis].
    Zavalishin IA; Gusev EI; Iakhno NN; Ronkin MA; Shmidt TE; Demina TL; Kugoev AI; Adarcheva LS; Niiazbekova AS; Zakharova MN; Peresedova AB; Toropina GG; Klishevskaia LA; Maksimenko IM; Krotenkova MV; Konovalov SN; Rebrova OIu; Zhuchenko TD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; Suppl():59-64. PubMed ID: 12418394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience in copaxon treatment in Russia].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Adarcheva LS; Zakharova MN; Niiazbekova AS; Askarova LSh; Rebrova OIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(8):29-31. PubMed ID: 16180496
    [No Abstract]   [Full Text] [Related]  

  • 6. Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate--a case report.
    Heesen C; Gbadamosi J; Schoser BG; Pöhlau D
    Eur J Neurol; 2001 Mar; 8(2):199. PubMed ID: 11285002
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients.
    Sánchez-de la Rosa R; Sabater E; Casado MA; Arroyo R
    J Med Econ; 2012; 15(3):424-33. PubMed ID: 22217249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
    Johnson KP; Due DL
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):205-14. PubMed ID: 19527092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glatiramer acetate therapy: the plot thickens.
    Karandikar NJ; Racke MK
    Arch Neurol; 2005 Jun; 62(6):858-9. PubMed ID: 15956155
    [No Abstract]   [Full Text] [Related]  

  • 10. [Use of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience of the Moscow multiple sclerosis center].
    Demina TL; Davydovskaia MV; Lashch NIu; Popova NF; Khachanova NV; Zhuchenko TD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; (Spec No 2):91-7. PubMed ID: 12938642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].
    Johnson KP; Brooks BR; Cohen JA; Ford CC; Goldstein J; Lisak RP; Myers LW; Panitch HS; Rose JW; Schiffer RB; Vollmer T; Weiner LP; Wolinsky JS;
    Neurology; 2001 Dec; 57(12 Suppl 5):S46-53. PubMed ID: 11902595
    [No Abstract]   [Full Text] [Related]  

  • 12. [Mechanisms of glatiramer acetate action in demyelinating diseases: antigen-specific, organ-specific or process-specific treatment].
    Boĭko AN; Zhuchenko TD; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; Suppl():52-8. PubMed ID: 12418393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The membrane stabilizing effect of glatiramer acetate in multiple sclerosis].
    Kravtsov IuI; Kicherova OA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(3):69-71. PubMed ID: 23612414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Beta-interferons in multiple sclerosis: comparative trials and potential individual selection in different types of the disease course].
    Boĭko AN; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; Suppl():65-71. PubMed ID: 12418395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Emerging new therapies for relapsing remitting multiple sclerosis].
    Anis S; Achiron A
    Harefuah; 2014 Nov; 153(11):658-62, 687, 686. PubMed ID: 25563027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
    Metz LM; Li D; Traboulsee A; Myles ML; Duquette P; Godin J; Constantin M; Yong VW;
    Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and tolerability of long-term using of glatimer acetate (copaxone): a 10 year-study in the Moscow Municipal Multiple Sclerosis center].
    Boĭko AN; Davydovskaia MV; Demina TL; Lashch NIu; Ovcharov VV; Popova EV; Popova NF; Romashkin AV; Boĭko OV; Khachanova NV; Sharanova SN; Shchur SG; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):86-92. PubMed ID: 22677683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
    Kornek B; Bernert G; Balassy C; Geldner J; Prayer D; Feucht M
    Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
    Makhani N; Ngan BY; Kamath BM; Yeh EA
    Neurology; 2013 Aug; 81(9):850-2. PubMed ID: 23884038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
    Bell C; Anderson J; Ganguly T; Prescott J; Capila I; Lansing JC; Sachleben R; Iyer M; Fier I; Roach J; Storey K; Miller P; Hall S; Kantor D; Greenberg BM; Nair K; Glajch J
    J Pharm Pract; 2018 Oct; 31(5):481-488. PubMed ID: 28847230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.